Gain Therapeutics, Inc.
GANX
$1.65
-$0.04-2.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 10.07M | 8.95M | 8.72M | 10.40M | 10.65M |
| Gross Profit | -10.07M | -8.95M | -8.72M | -10.40M | -10.65M |
| SG&A Expenses | 8.66M | 8.65M | 8.54M | 9.95M | 9.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.73M | 17.59M | 17.26M | 20.35M | 20.36M |
| Operating Income | -18.73M | -17.59M | -17.26M | -20.35M | -20.36M |
| Income Before Tax | -19.30M | -18.10M | -17.84M | -20.31M | -19.87M |
| Income Tax Expenses | 861.10K | 1.30M | 757.40K | 617.40K | 536.80K |
| Earnings from Continuing Operations | -20.16 | -19.39 | -18.59 | -20.93 | -20.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.16M | -19.39M | -18.59M | -20.93M | -20.41M |
| EBIT | -18.73M | -17.59M | -17.26M | -20.35M | -20.36M |
| EBITDA | -18.69M | -17.55M | -17.22M | -20.31M | -20.32M |
| EPS Basic | -0.62 | -0.64 | -0.65 | -0.89 | -0.95 |
| Normalized Basic EPS | -0.37 | -0.37 | -0.39 | -0.54 | -0.58 |
| EPS Diluted | -0.62 | -0.64 | -0.65 | -0.89 | -0.95 |
| Normalized Diluted EPS | -0.37 | -0.37 | -0.39 | -0.54 | -0.58 |
| Average Basic Shares Outstanding | 131.84M | 121.73M | 113.26M | 102.14M | 91.43M |
| Average Diluted Shares Outstanding | 131.84M | 121.73M | 113.26M | 102.14M | 91.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |